Mysoven

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mysoven

Property Description
Active Ingredient Acetylcysteine (N-acetyl-L-cysteine)
Form Solution, Powder, Effervescent Tablet
Pharmacological Class Mucolytic Agent, Antidote
Common Use Reducing thickness of respiratory secretions
Origin Synthetic derivative of L-cysteine

What Type of Medicine is Mysoven?

Mysoven is a medicinal product containing the active ingredient Acetylcysteine, which is chemically recognized as N-acetyl-L-cysteine. It is defined within the primary pharmacological class of mucolytic agents, a category of drugs developed to manage conditions involving excessive or thickened respiratory secretions. Acetylcysteine is a synthetic derivative of the amino acid L-cysteine, utilized for its structural properties. The drug holds a critical dual classification, as it is also clinically recognized as an essential antidote for acetaminophen (paracetamol) overdose. This dual utility reflects the medicine's established role in both respiratory care and specific toxicological management.

Composition and General Forms of Acetylcysteine

The active substance, Acetylcysteine, is a single-ingredient product formulated into various high-level dosage forms to accommodate different patient needs. These preparations commonly include sterile solution suitable for inhalation via nebulization or for intravenous (IV) injection in clinical settings. Additionally, the compound is available in forms for oral consumption, such as effervescent tablets or powder for oral solution. The availability across these distinct routes—oral, inhaled, and systemic—is a differentiating factor, allowing medical practitioners to address localized pulmonary challenges or acute systemic issues.

Mysoven's Primary Functional Purpose

The principal purpose of this mucolytic agent is to reduce the physical viscosity and adhesion of mucus within the respiratory tract, thereby facilitating its clearance. Acetylcysteine achieves this through chemical interaction with the mucoproteins. Furthermore, its crucial secondary function involves increasing the production of the antioxidant glutathione. This protective mechanism is fundamental to its application as a specific countermeasure in acute toxicological scenarios.

Regulatory References

  1. N-Acetylcysteine - StatPearls - NCBI Bookshelf

What side effects are possible with Mysoven?

Possible Side Effects and Safety Information

Official regulatory documentation classifies the possible adverse reactions of Acetylcysteine (Mysoven) primarily by system-organ class and frequency of occurrence. The safety profile is structured to distinguish between common expected effects and rare but serious events.

Frequency-Classified Adverse Reactions (Selected)

Frequency Classification Examples of Associated Effects
Uncommon (ge 1/1,000 to < 1/100) Hypersensitivity reactions (e.g., pruritus, rash), headache, tinnitus, nausea, vomiting, diarrhoea, abdominal pain, hypotension, tachycardia.
Rare (ge 1/10,000 to < 1/1,000) Dyspepsia, bronchospasm, difficulty breathing (dyspnoea).
Very Rare (< 1/10,000) Anaphylactic shock, haemorrhages (bleeding).
Not Known Severe skin reactions (e.g., Stevens-Johnson syndrome, Toxic Epidermal Necrolysis).

Documented Safety Considerations

Adverse reactions are formally reported across various systems, including the Immune, Gastrointestinal, Vascular, and Nervous Systems. Clinically significant events explicitly noted in regulatory sources include fatal or life-threatening anaphylaxis and the occurrence of severe skin reactions.

Specific safety constraints are documented for certain populations. The medicine is not to be used in children under 2 years of age due to the physiological inability to clear large volumes of secretions. Caution is advised in patients with a history of peptic ulcer. Furthermore, if bronchospasm occurs during use, treatment must be discontinued immediately.

Overdose and Emergency Response

Overdose and when to seek help — Official Regulatory Information for Mysoven

Regulatory documents define the Acetylcysteine overdose profile by detailing manifestations that necessitate urgent intervention.

Feature Official Regulatory Statements
Documented overdose presentations Overdose may present with severe anaphylactoid reactions, including rash, wheezing, flushing, and hypotension. Other presentations involve severe gastrointestinal symptoms like vomiting, and neurological effects such as confusion and seizures linked to hyponatraemia.
Physiological systems affected Respiratory, Cardiovascular, Nervous systems, and Fluid/Electrolyte balance.
Dose-related or exposure-related factors Intravenous administration errors resulting in excessive fluid volume are a documented risk factor for severe outcomes, including cerebral edema and brain herniation.
Population-specific overdose notes Pediatric patients or those weighing under 40 kg are listed as having an increased risk of severe fluid overload and hyponatraemia. Patients with a history of asthma or atopy are at an increased risk of anaphylactoid reactions.
When immediate medical help is required Seek immediate medical attention is required upon the onset of any serious or severe adverse reaction.

Official overdose statements:

  • Life-threatening anaphylaxis and severe systemic reactions are documented complications requiring immediate medical care.
  • The regulatory text mandates the immediate discontinuation of administration if a serious reaction or progressive bronchospasm is observed.
  • Although Acetylcysteine is the official antidote for acetaminophen overdose, treatment for an overdose of Acetylcysteine itself is limited to symptomatic and supportive measures.

Connection to the overall overdose profile:

The official guidance focuses on monitoring for severe anaphylactoid symptoms and systemic toxicity from administration errors that demand urgent intervention. This profile specifies the cessation of the drug and immediate supportive care to manage these documented, serious outcomes.

Therapeutic Uses of Mysoven

What Mysoven Treats: Main Uses and Benefits

Mysoven (Acetylcysteine) is relevant across two distinct clinical domains, supporting patients with severe airway congestion and those in acute toxicological states.


Targeted Relief for Tenacious Respiratory Secretions

This medication is used as a supportive measure for patients suffering from bronchopulmonary diseases, including Chronic Obstructive Pulmonary Disease (COPD), cystic fibrosis, and certain cases of acute pneumonia or bronchitis. It is applied in situations where highly viscous (thick and sticky) mucus creates noticeable physiological strain. A key therapeutic benefit is that it assists with addressing symptoms related to physical discomfort, which provides supportive relief from chest congestion and an ineffective, tiring cough. This supports the patient during difficult episodes by easing distress and helps improve day-to-day comfort during symptomatic periods.

"It is used across conditions presenting with acute episodes, where additional symptomatic support is needed."

Quick Fact: Relief for Viscous Mucus and Congestion


Critical Intervention for Acetaminophen Poisoning

Mysoven is used for managing acute toxicological states as an antidote in the treatment of acute acetaminophen (paracetamol) overdose. This application is applied across domains where additional symptomatic support is needed to address the severe systemic threat posed by the overdose. The benefit is that it assists with maintaining functional stability in conditions marked by increased physiological stress. It also contributes to easing distress during periods of heightened symptoms.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Official Contraindications and Exclusions

Use of Mysoven is officially contraindicated for individuals with a known hypersensitivity to the active ingredient, Acetylcysteine, or to any of the product's excipients. Due to the composition of certain oral forms, it is also contraindicated in patients with specific hereditary metabolic disorders, such as Phenylketonuria (PKU) or hereditary fructose intolerance.


Age and Comorbidity Restrictions

As a mucolytic agent, Mysoven is contraindicated in children under two years of age due to physiological limitations in their ability to clear bronchial secretions. However, for the antidote indication, use is permitted in pediatric patients weighing 5 kg or greater. Use is restricted and requires immediate discontinuation if bronchospasm occurs in patients with bronchial asthma. Caution is also advised for those with a history of peptic ulcers.


Reproductive Status Limitations

Official labeling restricts use during pregnancy to cases where it is clearly needed. Use while breastfeeding is generally not recommended due to insufficient data on the excretion of the substance into human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Acetylcysteine (Mysoven) details specific interaction patterns concerning pharmacodynamic potentiation, reduced drug exposure, and mandated administration timing. The use of certain antitussive drugs is advised against for concomitant administration due to the risk of reduced cough reflex and subsequent build-up of bronchial secretions.

Documented Pharmacodynamic Effects and Exposure Alteration

Co-administration with Nitroglycerin may result in a pharmacodynamic potentiation of the vasodilatory effect, which may lead to clinically significant hypotension requiring monitoring. Certain substances are documented to alter the absorption or concentration of Acetylcysteine or the co-administered drug. For instance, Activated Charcoal can reduce the effectiveness of Acetylcysteine due to reduced absorption. The combined use of Acetylcysteine with Carbamazepine may result in sub-therapeutic levels of Carbamazepine.

Mandatory Administration Timing Rules

For oral administration, specific timing constraints are necessary to prevent chemical inactivation or reduced bioavailability. Oral Antibiotics (e.g., certain tetracyclines, cephalosporins) must be administered at least two hours before or after Acetylcysteine. Similarly, Heavy Metal Salts (such as iron or gold compounds) should not be taken concomitantly, but at a different time of the day, due to the potential for reduced bioavailability. Furthermore, regulatory labels state that the stability and safety of mixing Acetylcysteine solution with other medicinal products in a nebulizer or syringe have not been established, imposing restrictions on combined preparation.

Finally, Acetylcysteine can interfere with the results of certain diagnostic procedures, specifically the colorimetric determination of salicylate and the determination of ketones in the urine.

Mechanism of Action

How Mysoven Works

Mysoven operates across distinct biochemical and cellular domains to modify specific signaling pathways. Its mechanism involves the regulation of overactive or dysregulated intracellular signaling cascades, which results in the precise modification of pathway activity within targeted biological systems.

Mysoven acts within domains involving receptor- or enzyme-mediated signaling by selectively engaging mechanisms that influence the activity of specific molecular targets. This initial modification of early molecular steps initiates or suppresses signaling sequences that propagate pathway activity downstream.

Furthermore, Mysoven influences systems where specific transmitters or mediators dominate. By modifying pathway activity, the compound restricts the magnitude of excessive mediator release or activity, which subsequently alters the characteristic of overactive physiological responses at the system level. This action is critical in modulating feedback regulation within pathways, leading to the establishment of an altered cellular state within the relevant biological systems.

Dosage and Administration Information

How to Use Mysoven

Acetylcysteine (Mysoven) is administered according to distinct protocols that depend entirely on its intended use—either as a mucolytic agent for respiratory secretions or as an antidote for acute poisoning.


Administration Routes and Dosing Patterns

The medicine is supplied in multiple forms to allow for several administration routes, including Intravenous (IV) Infusion, Oral Solution, Inhalation via nebulization, and direct Local Instillation.

Use-Case Primary Route Labeled Dosing Structure
Antidote (Systemic) IV Infusion or Oral Highly sequential and weight-based (mg/kg), administered over a fixed period.
Mucolytic (Local) Inhalation/Instillation Volume-based, typically 3 to 10 mL of solution per dose, administered on an intermittent, repeated schedule.

Standardized Administration Protocols

For its antidote use, the IV regimen requires a total of 300 mg/kg to be infused sequentially in three doses over a 21-hour period. The oral antidote regimen consists of a 140 mg/kg loading dose followed by 17 maintenance doses repeated every four hours, totaling 18 doses over 72 hours.

Proper administration often requires specific preparatory steps. The IV solution must be diluted prior to infusion using agents such as 5% Dextrose. For nebulization, a bronchodilator is typically administered 10 to 15 minutes prior to the acetylcysteine dose as a procedural requirement. Furthermore, the prepared oral antidote solution must be used within one hour of dilution, and the active ingredient should not be mixed with other medications in the same nebulizer or IV bag due to potential incompatibility. These instructions define the standardized procedural use of the medicine across approved applications.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Mysoven

Evidence for Use in Chronic Respiratory Conditions

This section summarizes the structure of clinical research, including placebo-controlled trials and systematic reviews, that have examined Acetylcysteine's role in the management of chronic conditions such as Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis, focusing on outcomes like exacerbation frequency and respiratory symptoms.

Studies reported measurements where the observed rate of exacerbations in some groups of patients with COPD/Chronic Bronchitis who were observed using the medicine for long durations was lower than in those receiving a placebo. Studies exploring long-term decline in lung function reported inconsistent findings regarding whether a difference was sustained. Systematic reviews indicate that trial results were often heterogeneous, meaning the observations varied widely across different study populations and protocols.

Evidence for Use in Acute Acetaminophen Overdose

This part will describe the robust body of evidence—primarily cohort studies and established clinical protocols—that addresses severe liver injury in acute toxicological states.

Studies consistently reported that the early initiation of Acetylcysteine was associated with a measured low incidence of severe hepatotoxicity in the observed populations. Researchers noted that survival rates described in large cohort studies were observed to be different when the medicine was initiated according to established protocols compared to historical data. Research describes that when treatment is delayed, the evidence shows patterns of greater incidence of liver injury and a greater likelihood of progression to systemic failure.

Long-Term Research and Follow-up Duration

For chronic respiratory conditions, research has explored short-term symptom changes as well as intermediate to long-term follow-up, with many studies observing responses over time intervals of 6 months to 12 months to measure outcomes related to exacerbation frequency.

However, evidence remains limited for long-term effects beyond the one-year mark for its mucolytic uses. This means that research provides context but not individual predictions about the very long-term course of the condition with continued use.

Key Studies & References

  1. N-acetylcysteine Treatment in Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis/Pre-COPD: Distinct Meta-analyses (2024)
  2. Clinical Practice Guidelines: Paracetamol poisoning (The Royal Children's Hospital, Australia)

Frequently Asked Questions (FAQ)

Common questions about Mysoven (FAQ)

Q: How quickly should I expect Mysoven to start working?

A: Official information does not provide a specific timeframe for when the general mucolytic (mucus-thinning) effect of Mysoven begins. However, when the medication is used as an antidote for acetaminophen overdose, early initiation, typically within eight hours, is associated with the best outcomes in achieving the intended protective effect.

Q: How long does the effect of one dose of Mysoven last?

A: The duration of effect for a single dose is not precisely defined in regulatory documents. For its approved uses, Mysoven dosing is scheduled with repetitions to maintain therapeutic levels, with doses often required every few hours (e.g., 2 to 6 hours) for mucolytic therapy.

Q: Is Mysoven safe for long-term use?

A: Studies referenced in regulatory summaries have observed patients using the medication for chronic respiratory conditions for periods ranging from six to twelve months. Official information indicates that the evidence regarding its effects for very long-term use (beyond one year) remains limited.

Q: Are there any stomach-related side effects from Mysoven?

A: Yes, official safety information documents gastrointestinal side effects. These reactions can include nausea, vomiting, diarrhoea, abdominal pain, and dyspepsia (indigestion), and they are classified as uncommon reactions.

Q: Does Mysoven interact with common pain relievers like ibuprofen?

A: Regulatory labeling specifies interactions with several other drug classes, such as nitroglycerin and certain antibiotics, but it does not specifically list an interaction with ibuprofen. Individuals using this medication are generally advised to inform a healthcare professional about all over-the-counter pain relievers they use.

Q: Does alcohol consumption affect how Mysoven works?

A: Specific, direct interactions between Mysoven and alcohol are not uniformly detailed in the primary regulatory labels. Consultation with a healthcare professional is appropriate to discuss the consumption of alcohol while using any medication.

Q: What kind of research supports the use of Mysoven?

A: The use of Mysoven is supported by clinical research, including systematic reviews and placebo-controlled trials for chronic respiratory conditions. Separately, robust cohort studies support its critical function as an antidote for acute acetaminophen overdose.

Q: Can Mysoven be used by people with high blood pressure?

A: Official adverse reaction lists mention hypotension (a drop in blood pressure) as a potential side effect. However, regulatory information does not provide specific advice or warnings for people who already have high blood pressure (hypertension).

Q: Can Mysoven be used by people with diabetes?

A: The medication is contraindicated in patients with specific hereditary metabolic conditions, such as hereditary fructose intolerance and Phenylketonuria (PKU). However, official documentation does not give specific guidance concerning the use of Mysoven for people with general diabetes.

Q: Are there generic versions of Mysoven available?

A: Yes, the active ingredient in Mysoven, Acetylcysteine, is widely available in generic formulations, including both injectable and oral effervescent forms. The specific availability of generic equivalents for the branded product may depend on the market.

Q: Can Mysoven interfere with lab test results?

A: Yes, regulatory documentation states that Mysoven can interfere with the results of certain diagnostic tests. This includes the determination of ketones in the urine and the colorimetric determination of salicylates.

Q: Is Mysoven meant for preventative use?

A: Official research summaries have observed that treatment with Mysoven was associated with a lower rate of exacerbations (worsening of symptoms) in patients with chronic respiratory conditions. This finding suggests a prophylactic, or preventative, benefit for this patient group.

Q: Are there any known food restrictions while taking Mysoven?

A: There are no general food restrictions associated with Mysoven. However, specific administration timing rules exist to prevent interactions with certain medications. For example, oral antibiotics and heavy metal salts should be taken at least two hours before or after Mysoven.

Q: Is Mysoven a prescription drug or over-the-counter?

A: Mysoven (Acetylcysteine) is classified as an FDA-approved prescription drug when used for its approved indications as a mucolytic or antidote. It is not an over-the-counter medicine.

Q: What should I do if I forget to take a dose of Mysoven?

A: The recommended protocol for a missed dose is generally to take it as soon as it is remembered. If it is nearly time for the next scheduled dose, the official guidance is to skip the missed one and continue the regular dosing schedule. It is advised not to take a double dose.

Q: Can I take Mysoven with food, or does it need to be on an empty stomach?

A: For some oral forms, patient information suggests that individuals can generally continue their normal diet while taking the medicine, unless otherwise instructed by their prescribing healthcare provider.

Q: Who is the manufacturer of Mysoven?

A: The manufacturer of the specific Mysoven product will be listed on the package insert and official drug labeling documents. Because Acetylcysteine is made by many companies, the manufacturer may vary depending on the specific product brand and formulation you receive.

Q: Where is Mysoven usually available for purchase?

A: As Mysoven is a prescription medication, it is typically available for purchase at licensed pharmacies. A valid prescription from a healthcare provider is required to obtain the medicine.

Q: What is the typical duration of treatment with Mysoven?

A: The duration of treatment varies significantly based on the reason for use. For acute acetaminophen overdose, the treatment protocol is fixed (e.g., 21 or 72 hours). For mucolytic use, the duration is highly individualized based on clinical need and symptoms.

Q: What is the patent status of Mysoven?

A: The active ingredient, Acetylcysteine, has expired patents. However, specific branded Mysoven formulations may be covered by active patents related to method of use or specific drug composition, with various expiration dates.

Q: Are there storage requirements for Mysoven (e.g., refrigeration)?

A: Official labeling requires that the powder or effervescent tablets be stored in the original packaging, protected from light and moisture. While undiluted sterile solutions are generally stored at room temperature, any opened or diluted solutions may have specific time limits for use and may sometimes require refrigeration.

Q: How often is Mysoven typically taken each day?

A: The frequency depends entirely on the approved use. For mucolytic therapy via nebulization, administration is typically scheduled to occur three to four times a day, though this can vary based on individual clinical needs.

How should Mysoven be stored and disposed of?

How to Store and Dispose of Mysoven (Acetylcysteine)

The storage and disposal requirements for Mysoven powder for oral solution are officially defined to maintain product stability and safety.

Storage Requirements

Mysoven must be stored in its original package to protect it from moisture and light, and should be kept in a cool, dry place. The product does not require any special temperature storage conditions. The medicine must be kept out of the sight and reach of children.

Once the powder is dissolved, the resulting solution must be administered immediately and must not be stored for later use. Do not use the medicine past the expiry date printed on the packaging.

Disposal Instructions

Proper disposal is required to prevent environmental harm. Unused or expired Mysoven must not be disposed of via wastewater or household waste. Disposal must be carried out in accordance with local regulations, and patients are advised to ask a pharmacist for guidance on how to safely discard the medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mysoven found in:

A-Z Index: